JNJ Stock Risk & Deep Value Analysis
Johnson & Johnson
DVR Score
out of 10
What You Need to Know About JNJ Stock
We analyzed Johnson & Johnson using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran JNJ through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Conservative. Here's what we found.
JNJ Risk Analysis & Red Flags
What Could Go Wrong
While JNJ is highly diversified, a major setback in its pharmaceutical pipeline, such as a late-stage clinical trial failure or a significant unexpected patent expiration, could temper revenue growth projections and lead to a mid-single-digit percentage share price decline over a few quarters.
Risk Matrix
Overall
Conservative
Financial
Low
Market
Low
Competitive
Medium
Execution
Low
Regulatory
Medium
Red Flags
- ⚠
None major identified; JNJ is a mature, stable company.
- ⚠
Ongoing litigation risks are inherent to the pharmaceutical industry, though JNJ has managed them effectively.
Upcoming Risk Events
- 📅
Major patent expiry for a blockbuster drug (e.g., Stelara biosimilar entry)
- 📅
Negative regulatory ruling for a pipeline candidate
- 📅
Significant product liability litigation outcomes
When to Reconsider
- 🚪
Significant and sustained deceleration in overall pharmaceutical segment growth below industry averages.
- 🚪
Repeated failures of late-stage pipeline assets without adequate replacement candidates.
- 🚪
Unexpected dividend cuts or suspension.
Unlock JNJ Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
JNJ offers a compelling investment for long-term oriented investors seeking stability, reliable dividend growth, and diversified exposure to the essential healthcare sector. Its robust R&D pipeline, strong financial health, and global reach position it as a resilient compounder, albeit without the hyper-growth potential for 10x returns within 3-5 years.
Is JNJ Stock Undervalued?
Unlock the full AI analysis for JNJ
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
JNJ Price Targets & Strategy
12-Month Target
$253.00
Bull Case
$265.00
Bear Case
$225.00
Valuation Basis
Based on 21x forward P/E applied to estimated FY26 EPS of $12.05, representing stable growth for a mega-cap.
Entry Strategy
Consider dollar-cost averaging near the $235-$240 support levels (e.g., 50-day SMA). Optimal entry on dips towards $225.
Exit Strategy
For long-term holders, maintain for dividend and capital appreciation. For short-term, take profit at $260, stop-loss at $220.
Portfolio Allocation
2-5% for conservative/moderate risk tolerance, due to its defensive nature and stability.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does JNJ Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable
Moat Sources
4 Identified
JNJ's moat is highly durable, stemming from its vast portfolio of patented drugs, complex medical devices, and deeply entrenched relationships within healthcare systems. Continuous R&D investment and a diversified business model ensure long-term competitive advantages despite individual product life cycles.
Moat Erosion Risks
- •Increased competition from biosimilars and generics for blockbuster drugs
- •Intensifying regulatory pressure on drug pricing and medical device approvals
- •Erosion of brand equity in specific consumer segments (post-Kenvue spin-off)
JNJ Competitive Moat Analysis
Sign up to see competitive advantages
JNJ Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. JNJ typically garners stable, long-term investor interest rather than speculative social media momentum due to its large-cap, defensive nature.
Institutional Sentiment
Positive. Institutions typically hold JNJ for long-term stability, dividend income, and defensive qualities. Recent analyst ratings are largely 'Buy' or 'Hold' with modest target price increases.
Insider Activity (Form 4)
Normal insider activity, with routine executive share sales for compensation or tax planning, and occasional purchases. No significant red flags indicating a change in internal conviction.
Options Flow
Normal options activity for a mega-cap, with balanced call/put volume, primarily used for hedging or income strategies rather than speculative directional bets.
Earnings Intelligence
Next Earnings
Estimated late April 2026 (for Q1 2026)
Surprise Probability
Medium
Historical Earnings Pattern
JNJ typically meets or slightly exceeds consensus estimates. The stock price reaction tends to be moderate, often moving within a 1-3% range on results, with larger movements if guidance is significantly revised.
Key Metrics to Watch
Competitive Position
Top Competitor
Abbott Laboratories (ABT)
Market Share Trend
Stable to slightly gaining market share in key therapeutic areas through innovation and strategic M&A, while managing patent expirations.
Valuation vs Peers
JNJ generally trades at a slight premium to highly diversified healthcare peers due to its exceptional scale, diversification, and robust R&D pipeline across both pharma and medtech. Its P/E is typically in line with or slightly above the sector average.
Competitive Advantages
- •Extensive R&D capabilities and pipeline across diverse healthcare segments
- •Globally recognized brand power and strong customer loyalty in consumer health (historically) and medical devices
- •Broad distribution networks and scale efficiencies
- •Diverse portfolio mitigates risks associated with single product failures or patent cliffs
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive JNJ Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated late April 2026)
- •Key pharmaceutical pipeline data readouts (e.g., Oncology, Immunology)
- •Regulatory approvals for new medical device innovations
Medium-Term (6-18 months)
- •Expansion of key pharmaceutical drugs into new geographic markets
- •Strategic bolt-on acquisitions in MedTech or Pharma
- •Launch of next-generation surgical robotics platforms
Long-Term (18+ months)
- •Sustained leadership in advanced therapies (e.g., cell & gene therapy)
- •Continued global demographic trends supporting healthcare demand
- •Diversification strategy leveraging AI in R&D and diagnostics
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for JNJ?
- ✓
Acceleration in pharmaceutical pipeline readouts and new product launches exceeding expectations.
- ✓
Sustained organic revenue growth above 6% annually.
- ✓
Successful integration of strategic acquisitions bolstering key segments.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Johnson & Johnson (JNJ)?
As of March 28, 2026, Johnson & Johnson has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the risk level for JNJ stock?
Our analysis rates Johnson & Johnson's overall risk as Conservative. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the JNJ DVR analysis updated?
Our AI-powered analysis of Johnson & Johnson is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 28, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for JNJ (Johnson & Johnson) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.